Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATF1
REST API REST API
Homo sapiens
ATF1 is differentially expressed in 276 experiments: 120 organism parts: cervix, prostate, ... (118 more);, 153 disease states: normal, cervical carcinoma, ... (151 more);, 92 cell types 319 cell lines 37 compound treatments and 72 other conditions.
Synonyms TREB36
Orthologs Q4H3R6_CIOIN (Ciona intestinalis)   atf1 (Danio rerio)   ATF1_BOVIN (Bos taurus)   Atf1 (Mus musculus)   Atf1 (Rattus norvegicus)   ATF1 (Gallus gallus)   CrebB-17A (Drosophila melanogaster)   atf1 (Xenopus laevis)   ATF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, DNA binding, protein binding, regulation of transcription, DNA-dependent, innate immune response, transcription, DNA-dependent, stress-activated MAPK cascade, sequence-specific DNA binding, protein dimerization activity, positive regulation of transcription from RNA polymerase II promoter, nucleus, protein heterodimerization activity, positive regulation of DNA replication, transcription factor complex, nucleoplasm, toll-like receptor 4 signaling pathway, positive regulation of neuron projection development, cellular protein complex assembly, toll-like receptor signaling pathway, response to cobalt ion, toll-like receptor 3 signaling pathway, nerve growth factor receptor signaling pathway, toll-like receptor 2 signaling pathway, protein complex binding, MyD88-dependent toll-like receptor signaling pathway, sequence-specific DNA binding transcription factor activity, MyD88-independent toll-like receptor signaling pathway, response to organic cyclic compound, toll-like receptor 1 signaling pathway, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term bZIP_1, bZIP_2, Coactivator_CBP_pKID, Leuzip_CREB, TF_bZIP
UniProt Accession P18846, B4DRF9, F8VRN2, F8VS03, F8VYN3, F8VYE5
Gene-Disease Assocation HISTIOCYTOMA, ANGIOMATOID FIBROUS
Search EB-eye ENSG00000123268
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-19397, ... (37 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
primary culture
2
E-GEOD-2450, E-GEOD-1657
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
SW480
2
E-MEXP-1014, E-MTAB-37
HL-60
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
313 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-19397, E-GEOD-3920, E-MEXP-750, E-MEXP-66, ... (44 experiments)

Factor Value U/D Experiments
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-26672, E-GEOD-13987
native skin
1
E-GEOD-3204
hematopoietic
1
E-GEOD-9894
primary fibroblast
1
E-MEXP-66
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MTAB-62, ... (59 experiments)

Factor Value U/D Experiments
cervical carcinoma
4
E-MTAB-62, E-GEOD-5823, E-MEXP-1331, E-MTAB-37
gastric carcinoma
2
E-GEOD-2685, E-MTAB-37
colon carcinoma
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
147 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (23 experiments)

Factor Value U/D Experiments
none
4
6
E-TABM-782, E-GEOD-5824, E-GEOD-20719, E-GEOD-412, E-GEOD-2803, ... (10 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
CNOT7+CNOT8
1
1
E-MEXP-2218
TGF-Beta1
1
E-MEXP-2645
glutamine
1
E-MEXP-1335
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-MEXP-1251, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-21138, E-GEOD-1751 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (8 experiments)

Genotype
studied in E-TABM-763, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-MEXP-2069, E-GEOD-1926, ... (38 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-MTAB-197, E-GEOD-4342

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.345 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM